A phase II study of atrasentan (ABT-627) plus pegylated liposomal encapsulated doxorubicin [doxorubicin liposomal] (Doxil) in patients with recurrent ovarian, fallopian tube, or peritoneal serous papillary adenocarcinoma following platinum + taxane therapy.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atrasentan (Primary) ; Doxorubicin liposomal (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

Most Recent Events

27 May 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.
27 May 2010 Actual end date changed from 1 Sep 2006 to 1 Mar 2009 as reported by ClinicalTrials.gov.
27 May 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight